-
DeferoxamineB in Ferroptosis Research Workflows
2026-08-20
DeferoxamineB gives cancer researchers a practical way to perturb iron availability, oxidative stress, and regulated cell death in controlled assays. Used as a mechanistic comparator rather than an assumed combination partner, it can clarify whether metabolic cancer therapies depend on iron-driven biology.
-
Carvedilol Phosphate: Reading IRI Signaling
2026-08-20
Carvedilol Phosphate offers a pharmacological lens for studying adrenergic control of hepatic ischemia–reperfusion injury. This article connects beta-receptor perturbation with the hepatocyte Arrb2–6-ketoLCA–macrophage axis and provides assay-design guidance beyond conventional protocol troubleshooting.
-
Penicillin G Sodium: Applied Workflow Guide
2026-08-19
Penicillin G Sodium supports controlled Gram-positive infection models, contamination management, and exposure-schedule experiments when bacterial susceptibility and solution stability are verified. This workflow guide connects antimicrobial readouts with orthogonal cell-assay design while clarifying where evidence supports use—and where it does not.
-
Ruxolitinib, DRP1, and Cell Death in ATC
2026-08-19
The reference study identifies a JAK1/2–STAT3–DRP1 axis that connects ruxolitinib treatment to impaired mitochondrial fission and caspase-dependent apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma. Its findings position mitochondrial-state measurements, including carefully controlled JC-1 readouts, as useful complementary evidence for studying treatment-associated mitochondrial dysfunction rather than as standalone proof of mechanism.
-
Sulfaphenazole Optimization for TB and CYP2C9 Selectivity
2026-08-18
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing unwanted CYP2C9 inhibition. Compound 10d provided the clearest balance, combining a reported M. tuberculosis MIC of 5.69 μg/mL with CYP2C9 inhibition above 10 μM and low cytotoxicity.
-
α-Bungarotoxin for nicotinic receptor blockade
2026-08-18
α-Bungarotoxin provides a high-affinity way to test α7 nicotinic acetylcholine receptor dependence in neural, neuromuscular, and placental models. This guide translates recent necroptosis research into practical assay design, control selection, and troubleshooting strategies.
-
Syringin N1347: Reliable Cell Assay Workflows
2026-08-17
Learn how Syringin (SKU N1347) can support reproducible cell viability, proliferation, cytotoxicity, and apoptosis research. This scenario-based guide covers assay interpretation, solvent compatibility, protocol optimization, RCC mechanism studies, and evidence-based product selection.
-
FK866 (APO866): A Translational NAD Strategy
2026-08-17
FK866 (APO866) offers a precise way to interrogate NAMPT dependence, NAD depletion, mitochondrial injury, and treatment resistance. This thought-leadership analysis connects AML-focused metabolism research with emerging evidence that NAD biology shapes PARP inhibitor resistance, while outlining practical strategies for rigorous translational studies.
-
Calpain Inhibitor I, ALLN: Practical Workflow
2026-08-16
Calpain Inhibitor I, ALLN (SKU A2602) is a cysteine-protease inhibitor for controlled studies of calpain and cathepsin contributions to apoptosis, inflammation, and ischemia-reperfusion injury. It is water-insoluble and should be prepared in DMSO or ethanol with matched vehicle controls; it is for research use only and does not provide a validated clinical or diagnostic protocol.
-
Steroid Lysis of Protoplasts: Mechanistic Insights
2026-08-15
Smith and Shay used osmotically fragile Sarcina lutea protoplasts to separate cell-wall effects from direct membrane injury by synthetic antimicrobial steroids. Their protection and surfactant experiments support membrane disruption as a principal mechanism while also showing that polyamines, divalent cations, aggregation, and lipid environments can strongly alter the lysis readout.
-
Human SAN-Plexus Assembloids Model Pacemaker Maturation
2026-08-14
The reference study develops human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac ganglionated plexus, and atrial-like tissues to model neuro-cardiac control of pacemaker maturation. By integrating electrophysiology with human SAN spatial transcriptomics, the authors identify a CGPO-derived prosaposin–GPR37 signaling program that supports pacemaker development and provides a framework for studying conduction dysfunction.
-
Cx43/NF-κB Control of AngII Macrophage Polarization
2026-08-14
The reference study shows that angiotensin II drives RAW264.7 macrophages toward an M1-like inflammatory phenotype through coordinated activation of Cx43 and NF-κB p65. Pharmacologic inhibition of either component reduced inflammatory markers, positioning Cx43 as a mechanistic entry point for studying macrophage-mediated cardiovascular inflammation while also defining important limits for translation to other systems.
-
Machine Learning for Senolytic Discovery
2026-08-13
The Nature Communications study developed machine-learning models from published screening data to identify senolytic candidates despite limited and heterogeneous training datasets. Computational screening followed by human-cell validation identified ginkgetin, periplocin, and oleandrin, demonstrating a cost-conscious route for early senolytic discovery while highlighting the need for cell-type and senescence-context controls.
-
Risedronate Sodium: Assay Design Beyond Bone
2026-08-13
Risedronate Sodium is an FPP synthase inhibitor whose value extends from osteoclast-mediated bone resorption inhibition to carefully bounded lung and cancer research. This article presents an assay-centered framework that distinguishes direct evidence, cross-domain hypotheses, delivery effects, and practical endpoint selection.
-
Ibrexafungerp Activity Against Resistant Candida auris
2026-08-12
Wiederhold and colleagues combined broth microdilution testing with a delayed-treatment murine model to evaluate ibrexafungerp against fluconazole-resistant Candida auris. The study found consistent in vitro activity and improved survival and kidney fungal-burden outcomes with ibrexafungerp and caspofungin, supporting glucan-targeted therapy as a research focus for invasive candidiasis.